Avidity Biosciences, Inc. — Director's Dealing 2024

Sep 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2024-09-11

Reporting Person: Flanagan W. Michael (CSTO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-11	Common Stock	M	62500	$26.75	Acquired	138265	Direct
2024-09-11	Common Stock	S	62500	$40.4002	Disposed	75765	Direct
2024-09-11	Common Stock	M	34000	$22.47	Acquired	109765	Direct
2024-09-11	Common Stock	S	34000	$40.3987	Disposed	75765	Direct
2024-09-11	Common Stock	S	14894	$40.3972	Disposed	60871	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-11	Stock Option (Right to Buy)	$26.75	M	62500	Disposed	2031-01-20	Common Stock (62500)	Direct
2024-09-11	Stock Option (Right to Buy)	$22.47	M	34000	Disposed	2033-01-19	Common Stock (34000)	Direct

Footnotes

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.75 to $41.00. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.80 to $41.00. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The sales reported on this row were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024 by the Reporting Person.

F5: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $40.95. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: 25% of the shares subject to the option vested on January 21, 2022, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F7: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.